Alemtuzumab: non-autoimmune complications
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Alemtuzumab: non-autoimmune complications. Flushing, Headache, Pruritus, Rash, Fever. Fully referenced neurology checklist.
Cytokine release infusion-related syndrome
- Flushing
- Headache
- Pruritus
- Rash
- Fever
Cardiovascular infusion-related side effects
Locked: subscribe to see this section.
Infections
Locked: subscribe to see this section.
Malignancies
Locked: subscribe to see this section.
Gastrointestinal
Locked: subscribe to see this section.
Inflammatory
Locked: subscribe to see this section.
Pulmonary
Locked: subscribe to see this section.
Miscellaneous side effects
Locked: subscribe to see this section.
References
- Coles AJ, Cohen JA, Fox EJ, et al; CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 2017; 89:1117-1126.
- Ferraro D, Camera V, Vitetta F, et al. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. Neurology 2018; 90:852-854.
- Havrdova E, Arnold DL, Cohen JA, et al; CARE-MS I and CAMMS03409 Investigators. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 2017; 89:1107-1116.
- Pfeuffer S, Beuker C, Ruck T, et al. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. Neurology 2016; 87:2380-2381.
- Croteau D, Flowers C, Kulick CG, Brinker A, Kortepeter CM. Acute acalculous cholecystitis: a new safety risk for patients with MS treated with alemtuzumab. Neurology 2018; 90:e1548-e1552.
- And 19 more. Subscribe to see the full list
